So low… so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors

Eur Heart J. 2018 Feb 1;39(5):382-384. doi: 10.1093/eurheartj/ehx742.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents*
  • Cholesterol, LDL
  • Humans
  • Proprotein Convertase 9*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • alirocumab